<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39398026</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Epidemiological and immunological characteristics of middle-aged and elderly people in housing estates after Omicron BA.5 wave in Jinan, China.</ArticleTitle><Pagination><StartPage>e38382</StartPage><MedlinePgn>e38382</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38382</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38382</ELocationID><Abstract><AbstractText>A great number of COVID-19 patients was caused by Omicron BA.5 subvariant between December 2022 and January 2023 after the end of the zero-COVID-19 policy in China. In this study, we clarified the epidemiological and immunological characteristics of 457 enrolled middle-aged and elderly population in two housing estates after Omicron BA.5 wave. A total of 89.9 % (411/457) individuals have suffered Omicron BA.5 infection, among which 78.1 % (321/411) were symptomatic. The elderly patients were more likely to show fatigue and had longer symptomatic period than that of middle-aged patients post Omicron BA.5 infection. Omicron XBB and BA.2.86 subvariants extensively escaped the immunity elicited by Omicron BA.5 infection. The level of neutralizing antibody was mostly affected by vaccination doses rather than underlying disease status in these participants. It is very important to strengthen the epidemiological investigation and immune resistance assessment among elderly population for control of emerging SARS-CoV-2 variants.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Xin-Jing</ForeName><Initials>XJ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biotatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Licheng Center for Disease Control and Prevention, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Licheng Center for Disease Control and Prevention, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wang-Qian</ForeName><Initials>WQ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biotatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jin-Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Chen-Long</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ti</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shandong Center for Disease Control and Prevention, Jinan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guo-Lin</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Li-Qun</ForeName><Initials>LQ</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biotatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Elderly population</Keyword><Keyword MajorTopicYN="N">Epidemiological characteristics</Keyword><Keyword MajorTopicYN="N">Neutralizing antibody</Keyword><Keyword MajorTopicYN="N">Omicron BA.5</Keyword><Keyword MajorTopicYN="N">Vaccination doses</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398026</ArticleId><ArticleId IdType="pmc">PMC11467590</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38382</ArticleId><ArticleId IdType="pii">S2405-8440(24)14413-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Council., J.P.a.C.M.o.S  Notice on further optimizing epidemic prevention and control measures of COVID-19. 2022. https://www.gov.cn/xinwen/2022-12/07/content_5730475.htm</Citation></Reference><Reference><Citation>Prevention, C.C.f.D.C.a. Epidemic situation of COVID-19 infection in China. 2023. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202303/t20230304_264035.html</Citation></Reference><Reference><Citation>Fu D., He G., Li H., et al. Effectiveness of COVID-19 vaccination against SARS-CoV-2 omicron variant infection and symptoms - China, december 2022-february 2023. China CDC Wkly. 2023;5:369–373. doi: 10.46234/ccdcw2023.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2023.070</ArticleId><ArticleId IdType="pmc">PMC10184382</ArticleId><ArticleId IdType="pubmed">37197449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Qin C., Liu M., et al. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infectious diseases of poverty. 2021;10:132. doi: 10.1186/s40249-021-00915-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00915-3</ArticleId><ArticleId IdType="pmc">PMC8590867</ArticleId><ArticleId IdType="pubmed">34776011</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Beltran W.F., Lam E.C., St Denis K., et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383.e2379. doi: 10.1016/j.cell.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC7953441</ArticleId><ArticleId IdType="pubmed">33743213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann N.P., Miller J., Collier A.Y., et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 2022;387:86–88. doi: 10.1056/NEJMc2206576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J., Hachmann N.P., Collier A.Y., et al. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N. Engl. J. Med. 2023;388:662–664. doi: 10.1056/NEJMc2214314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214314</ArticleId><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S., Liu L., Guo Y., et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604:553–556. doi: 10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue C., Song W., Wang L., et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Lancet Infect. Dis. 2023;23:278–280. doi: 10.1016/S1473-3099(23)00010-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00010-5</ArticleId><ArticleId IdType="pmc">PMC9897732</ArticleId><ArticleId IdType="pubmed">36746173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasoba D., Uriu K., Plianchaisuk A., et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect. Dis. 2023;23:655–656. doi: 10.1016/S1473-3099(23)00278-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00278-5</ArticleId><ArticleId IdType="pmc">PMC10156138</ArticleId><ArticleId IdType="pubmed">37148902</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Zhang R.M., et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. Lancet Infect. Dis. 2023;23:e397–e398. doi: 10.1016/S1473-3099(23)00555-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00555-8</ArticleId><ArticleId IdType="pubmed">37708906</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N., Collier A.Y., Hachmann N.P., et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine. 2023;41:6904–6909. doi: 10.1016/j.vaccine.2023.10.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.10.051</ArticleId><ArticleId IdType="pmc">PMC10842519</ArticleId><ArticleId IdType="pubmed">37872011</ArticleId></ArticleIdList></Reference><Reference><Citation>Stærke N.B., Reekie J., Nielsen H., et al. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. Nat. Commun. 2022;13:4466. doi: 10.1038/s41467-022-32254-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32254-8</ArticleId><ArticleId IdType="pmc">PMC9342834</ArticleId><ArticleId IdType="pubmed">35915081</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27:2032–2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang P.O., Govind S., Bokum A.T., et al. Immune senescence and vaccination in the elderly. Current topics in medicinal chemistry. 2013;13:2541–2550. doi: 10.2174/15680266113136660181.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/15680266113136660181</ArticleId><ArticleId IdType="pubmed">24066892</ArticleId></ArticleIdList></Reference><Reference><Citation>Causa R., Almagro-Nievas D., Rivera-Izquierdo M., et al. Antibody response 3 Months after 2 doses of BNT162b2 mRNA COVID-19 vaccine in residents of long-term care facilities. Gerontology. 2022;68:910–916. doi: 10.1159/000519711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000519711</ArticleId><ArticleId IdType="pmc">PMC8678266</ArticleId><ArticleId IdType="pubmed">34758461</ArticleId></ArticleIdList></Reference><Reference><Citation>Canaday D.H., Carias L., Oyebanji O.A., et al. Reduced BNT162b2 messenger RNA vaccine response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-Naive nursing home residents. Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America. 2021;73:2112–2115. doi: 10.1093/cid/ciab447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab447</ArticleId><ArticleId IdType="pmc">PMC8240817</ArticleId><ArticleId IdType="pubmed">33993265</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi K., Horiuchi S., Frere J., et al. A diminished immune response underlies age-related SARS-CoV-2 pathologies. Cell Rep. 2022;39 doi: 10.1016/j.celrep.2022.111002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111002</ArticleId><ArticleId IdType="pmc">PMC9181267</ArticleId><ArticleId IdType="pubmed">35714615</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, february 12-march 16, 2020. MMWR. Morbidity and mortality weekly report. 2020;69:343–346. doi: 10.15585/mmwr.mm6912e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6912e2</ArticleId><ArticleId IdType="pmc">PMC7725513</ArticleId><ArticleId IdType="pubmed">32214079</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., He Y., Lan X., et al. Epidemiological and clinical features of children with the Omicron BA.5.2 subvariant in Guangzhou. Signal Transduct Target Ther. 2023;8:163. doi: 10.1038/s41392-023-01372-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01372-0</ArticleId><ArticleId IdType="pmc">PMC10130145</ArticleId><ArticleId IdType="pubmed">37185317</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., Wang C., Li X., et al. Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing. Virol. J. 2023;20:209. doi: 10.1186/s12985-023-02177-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02177-x</ArticleId><ArticleId IdType="pmc">PMC10492331</ArticleId><ArticleId IdType="pubmed">37684638</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Xue Q., Zhang H., et al. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination. Emerg Microbes Infect. 2023 doi: 10.1080/22221751.2023.2249121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2249121</ArticleId><ArticleId IdType="pmc">PMC10524800</ArticleId><ArticleId IdType="pubmed">37668156</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Zhao S., Chong K.C., et al. Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen. Lancet Infect. Dis. 2023;23:403–404. doi: 10.1016/S1473-3099(23)00112-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00112-3</ArticleId><ArticleId IdType="pubmed">36803917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat. Protoc. 2020;15:3699–3715. doi: 10.1038/s41596-020-0394-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0394-5</ArticleId><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J., Li Q., Wu J., et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–686. doi: 10.1080/22221751.2020.1743767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1743767</ArticleId><ArticleId IdType="pmc">PMC7144318</ArticleId><ArticleId IdType="pubmed">32207377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.J., Li L.B., Peng H.H., et al. Neutralization against XBB.1 and XBB.1.5 after omicron subvariants breakthrough infection or reinfection. Lancet Reg Health West Pac. 2023;33 doi: 10.1016/j.lanwpc.2023.100759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100759</ArticleId><ArticleId IdType="pmc">PMC10114502</ArticleId><ArticleId IdType="pubmed">37090240</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Liu X., Gu Y., et al. Distinct and relatively mild clinical characteristics of SARS-CoV-2 BA.5 infections against BA.2. Signal Transduct Target Ther. 2023;8:171. doi: 10.1038/s41392-023-01443-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01443-2</ArticleId><ArticleId IdType="pmc">PMC10132431</ArticleId><ArticleId IdType="pubmed">37100801</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan X., Huang Q., Dong M., et al. SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022. J. Infect. 2023 doi: 10.1016/j.jinf.2023.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.08.010</ArticleId><ArticleId IdType="pubmed">37652314</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X.J., Ji B., Shang C., et al. Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection. iScience. 2024;27 doi: 10.1016/j.isci.2024.110283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2024.110283</ArticleId><ArticleId IdType="pmc">PMC11260851</ArticleId><ArticleId IdType="pubmed">39040063</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X.J., Liu X.L., Gu H.J., et al. SARS-CoV-2 reinfection broadens the antibody responses and promotes the phenotypic differentiation of virus-specific memory T cells in adolescents. J. Med. Virol. 2024;96 doi: 10.1002/jmv.29873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29873</ArticleId><ArticleId IdType="pubmed">39165041</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Jian F., et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis. 2023;23:e457–e459. doi: 10.1016/s1473-3099(23)00573-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(23)00573-x</ArticleId><ArticleId IdType="pubmed">37738994</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X.J., Liu X.L., Liang Y.M., et al. Epidemiological characteristics and antibody kinetics of elderly population with booster vaccination following both Omicron BA.5 and XBB waves in China. J. Med. Virol. 2024;96 doi: 10.1002/jmv.29640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29640</ArticleId><ArticleId IdType="pubmed">38699969</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., et al. Protection against SARS-CoV-2 after covid-19 vaccination and previous infection. N. Engl. J. Med. 2022;386:1207–1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashrafian F., Bagheri Amiri F., Bavand A., et al. A comparative study of immunogenicity, antibody persistence, and safety of three different COVID-19 boosters between individuals with comorbidities and the normal population. Vaccines. 2023;11 doi: 10.3390/vaccines11081376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11081376</ArticleId><ArticleId IdType="pmc">PMC10459403</ArticleId><ArticleId IdType="pubmed">37631944</ArticleId></ArticleIdList></Reference><Reference><Citation>Soegiarto G., Wulandari L., Purnomosari D., et al. Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40:4046–4056. doi: 10.1016/j.vaccine.2022.05.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.059</ArticleId><ArticleId IdType="pmc">PMC9135674</ArticleId><ArticleId IdType="pubmed">35660034</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>